Muse bio secures $23M Series B financing led by Venrock

Muse bio, a privately-held company leading the development of next-generation genome engineering capabilities, today announced the completion of a $23 million Series B financing. The oversubscribed financing was led by Venrock and included investments from Foresite Capital and Paladin Capital as well as both Series A investors, NanoDimension and Spruce/MLS.

PhishMe Reports Explosive Growth: Annual Run Rate Approaches $50 Million

PhishMe Inc., the leading provider of human phishing defense solutions, today announced another year of record growth, with Annual Run Rate (ARR) approaching $50 million. PhishMe’s more than 300 employees now serve 1,200 enterprise customers world-wide to defend against cybercriminals, hacktivists and state-sponsored hackers.

Page 1 of 1712345...10...Last »